澳大利亚全国推广HIV暴露前预防后使用PrEP的男男性行为者细菌性性传播感染发病率的真实世界趋势:哨点监测数据分析
该研究分析了2016年1月1日至2019年12月31日澳大利亚37家哨点诊所中22 730名使用PrEP的HIV阴性男男性行为者的临床数据,采用重复检测法计算衣原体、淋病、梅毒及任何STI的发病率。结果显示衣原体和淋病发病率在观察前18个月下降后趋于稳定,而梅毒发病率上升;较晚启动PrEP者前瞻性STI风险较低。
要点
- 衣原体发病率从2016年下半年48.7例/100人年降至2019年下半年42.0例/100人年(IRR 0.98,95%CI 0.97-0.99;p=0.0031)。
- 淋病发病率从2016年下半年45.5例/100人年降至2019年下半年37.2例/100人年(IRR 0.97,95%CI 0.96-0.98;p<0.0001)。
- 梅毒发病率从2016年下半年6.2例/100人年升至2019年下半年9.8例/100人年(IRR 1.08,95%CI 1.05-1.10;p<0.0001)。
核心结论
- 在澳大利亚使用PrEP的男男性行为者中,衣原体和淋病发病率在PrEP推广初期最高,随后在更广泛PrEP使用后稳定在略低水平,而梅毒发病率上升。
- 较晚年份启动PrEP者前瞻性STI风险较低, contributed to observed trends。
- 广泛PrEP推广可促进STI筛查和检测增加。
研究设计与样本
- 分析2016年1月1日至2019年12月31日澳大利亚37家哨点监测诊所中HIV阴性、年龄≥16岁、已开具PrEP的男男性行为者的关联临床数据。
- 纳入观察期内至少接受两次STI检测的患者,共22 730名男性纳入分析。
- 采用重复检测法计算衣原体、淋病、梅毒及任何STI在个体PrEP使用期间的发病率,使用负二项回归计算每6个月期间估计变化的发病率比(IRR)。
主要发现
- 衣原体:22 034名男性中6630名(30.1%)诊断11 351例感染,25 991.2人年PrEP使用,发病率43.7例/100人年(95%CI 42.9-44.5);从2016年7-12月48.7例/100人年降至2019年7-12月42.0例/100人年(IRR 0.98,95%CI 0.97-0.99;p=0.0031)。
- 淋病:21 845名男性中5885名(26.9%)诊断9391例感染,24 858.7人年PrEP使用,发病率37.8例/100人年(95%CI 37.0-38.5);从2016年7-12月45.5例/100人年降至2019年7-12月37.2例/100人年(IRR 0.97,95%CI 0.96-0.98;p<0.0001)。
- 梅毒:19 262名男性中1488名(7.7%)诊断2062例感染,21 978.9人年PrEP使用,发病率9.4例/100人年(95%CI 9.0-9.8);从2016年7-12月6.2例/100人年升至2019年7-12月9.8例/100人年(IRR 1.08,95%CI 1.05-1.10;p<0.0001)。
- 衣原体和淋病发病率下降在观察前18个月最显著,此后稳定。
关键数值与推荐
- 衣原体发病率每6个月估计变化IRR 0.98(95%CI 0.97-0.99;p=0.0031)。
- 淋病发病率每6个月估计变化IRR 0.97(95%CI 0.96-0.98;p<0.0001)。
- 梅毒发病率每6个月估计变化IRR 1.08(95%CI 1.05-1.10;p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although data from large implementation trials suggest that sexually transmissible infection (STI) risk increases among gay and bisexual men who initiate HIV pre-exposure prophylaxis (PrEP), there are few data on the trends in population-level STI incidence in the years following widespread PrEP implementation. We aimed to describe trends in bacterial STI incidence among gay and bisexual men using PrEP across Australia in the context of broad PrEP availability through Australia's subsidised medicines scheme. METHODS: We analysed linked clinical data from HIV-negative gay and bisexual men aged 16 years or older who had been prescribed PrEP across a sentinel surveillance clinical network, including 37 clinics in Australia, between Jan 1, 2016, and Dec 31, 2019. Patients were included if they had STI testing at least twice during the observation period. Repeat testing methods were used to calculate chlamydia, gonorrhoea, syphilis, and any STI incidence rates during individuals' periods of PrEP use. Incidence rate ratios (IRRs) for estimated change in incidence per half calendar year (6-month) period were calculated using negative binomial regression. Secondary analyses compared STI incidence rates across individuals initiating PrEP in each year from 2016 to 2019, as well as by length of time using PrEP (per each additional 6 months of PrEP use). FINDINGS: 22 730 men were included in the analyses. During the observation period, 11 351 chlamydia infections were diagnosed in 6630 (30·1%) of 22 034 men over 25 991·2 person-years of PrEP use (incidence rate 43·7 cases [95% CI 42·9-44·5] per 100 person-years). Chlamydia incidence decreased from 48·7 cases per 100 person-years in July-December, 2016, to 42·0 cases per 100 person-years in July-December, 2019 (IRR for estimated change per 6-month period 0·98 [95% CI 0·97-0·99]; p=0·0031). 9391 gonorrhoea infections were diagnosed in 5885 (26·9%) of 21 845 men over 24 858·7 person-years of PrEP use (incidence rate 37·8 cases [95% CI 37·0-38·5] per 100 person-years). Gonorrhoea incidence decreased from 45·5 cases per 100 person-years in July-December, 2016, to 37·2 cases per 100 person-years in July-December, 2019 (IRR 0·97 [95% CI 0·96-0·98]; p<0·0001). Declines in chlamydia and gonorrhoea incidence were most prominent in the first 18 months of observation and incidence was stable thereafter. 2062 syphilis infections were diagnosed in 1488 (7·7%) of 19 262 men over 21 978·9 person-years of PrEP use (incidence rate 9·4 cases [95% CI 9·0-9·8] per 100 person-years). Syphilis incidence increased from 6·2 cases per 100 person-years in July-December, 2016, to 9·8 cases per 100 person-years in July-December, 2019 (IRR 1·08 [95% CI 1·05-1·10]; p<0·0001). INTERPRETATION: Chlamydia and gonorrhoea incidence among gay and bisexual men using PrEP were highest in the early months of PrEP implementation in Australia and stabilised at slightly lower rates thereafter following wider PrEP uptake. Lower prospective STI risk among people initiating PrEP in later years contributed to the observed trends in STI incidence. Widespread PrEP implementation can contribute to increased STI screening and detection. FUNDING: Australian Department of Health, National Health and Medical Research Council.
引用
- Traeger MW, Guy R, Asselin J, et al. Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data. Lancet Infect Dis. 2022. PMID: 35643090. doi:10.1016/S1473-3099(22)00175-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。